AGAP3

Across TCGA pan-cancer cohorts, AGAP3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AGAP3 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher AGAP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AGAP3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, LUAD, and COAD are the cancer types where AGAP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.673	0.983	<.001	36	view →
LUAD	OS	Median	All	0.251	0.790	<.001	28	view →
COAD	DFS	Median	All	0.192	0.530	.012	8	view →
UCEC	DFS	Median	II,III,IV	0.915	0.440	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AGAP3–THYM (OS)

Open the THYM breakdown →